Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving Margins ⢠Strong Liquidity ⢠Ongoing Dilution PLSE's operating metrics and liquidity improved, but persistent losses, negative cash flow, dilution, and an extreme valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Constructive uptrend ⢠$55 resistance ⢠$49 risk Support Level: $49.00â$50.00; stronger support $47.50â$48.80 Resistance Level: $55.20 PLSE remains constructively bullish over the last month, but a break above $55.20 favors continuation while a sustained drop below $49 signals correction risk.
Sentiment & News
Key News Insights: ⢠Study Enrollment Complete ⢠Analyst Buy Rating ⢠Institutional Buying Pulse Biosciences gained investor and analyst momentum while advancing its thyroid-nodule clinical program through completed enrollment.
AI Summary
PLSE has shifted from a funding-survival story to a high-valuation clinical-conversion bet: its strong cash position can fund key trials, but investors should demand compelling PRECISE-BTN and NANOPULSE-AF efficacy, safety, and adoption evidence before underwriting further upside, as delays or mixed data could trigger dilution and sharp downside.
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |